More interesting news around PD-L1 for use in Classical Hodgkin lymphoma with specific indications as below. Another increasingly common example of companion diagnostics and personalized immunotherapies. On May 17, 2016, the U.S. Food and Drug...

SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that...